Trial Profile
Clinical evaluation of tebipenem pivoxil in the treatment of child community-acquired bacterial pneumonia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2018
Price :
$35
*
At a glance
- Drugs Tebipenem pivoxil (Primary) ; Ampicillin; Ampicillin/sulbactam
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- 29 Nov 2018 Status changed from recruiting to discontinued.
- 10 Jul 2014 New trial record